

Application No.: 10/810,649
 Amendment dated October 27, 2005
 Response to Office Action dated May 3, 2005

Docket No.: 22116-00002-US2


AMENDMENT TO CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

Please cancel claims 3-5, 11-28 and 31 without prejudice to their reentry at some later date.

Listing of Claims

1. (Currently Amended) A polyamine having the structure




wherein, n can be 0 to 8 and the aminomethyl functionality can be ortho, meta or para substituted, R is hydrogen, ~~CH₃, CH₂CH₃, 2-aminoethyl, 3-aminopropyl, 4-aminobutyl, 5-aminopentyl, 6-aminohexyl, 7-aminoheptyl, or 8-aminooctyl, N-methyl-2-aminoethyl, N-methyl-3-aminopropyl, N-methyl-4-aminobutyl, N-methyl-5-aminopentyl, N-methyl-6-aminohexyl, N-methyl-7-aminoheptyl, N-methyl-8-aminooctyl, N-ethyl-2-aminoethyl, N-ethyl-3-aminopropyl, N-ethyl-4-aminobutyl, N-ethyl-5-aminopentyl, N-ethyl-6-aminohexyl, N-ethyl-7-aminoheptyl or N-ethyl-8-aminooctyl~~ and R₁ is a moiety selected from the group consisting of a hydrogen or a straight or branched C1-20 saturated or unsaturated aliphatic; aliphatic amine except for propylamine when R = H, n=1 and the aminomethyl functionality is para substituted; an alicyclic; single or multi-ring aromatic; single or multi-ring aryl substituted aliphatic; aliphatic substituted single or multi-ring aromatic; a single or multi-ring heterocyclic; a single or multi-ring heterocyclic substituted aliphatic; an aliphatic substituted aromatic; and halogenated forms thereof, and wherein said polyamine is a non-symmetrical ~~xylene~~.

Application No.: 10/810,649
 Amendment dated October 27, 2005
 Response to Office Action dated May 3, 2005

Docket No.: 22116-00002-US2

2 (Currently Amended) A polyamine having the structure



wherein n can be 0 to 8, and the aminomethyl functionality can be ortho, meta or para substituted, R is hydrogen ~~-CH₃, -CH₂CH₃~~, 2-aminoethyl, 3-aminopropyl, 4-aminobutyl, 5-aminopentyl, 6-aminohexyl, 7-aminoheptyl, 8-aminocetyl, ~~N-methyl-2-aminoethyl, N-methyl-3-aminopropyl, N-methyl-4-aminobutyl, N-methyl-5-aminopentanyl, N-methyl-6-aminohexyl, N-methyl-7-aminoheptyl, N-methyl-8-aminoethyl, N-methyl-6-aminohexyl, N-methyl-7-aminoheptyl, N-methyl-8-aminoethyl, N-ethyl-2-aminoethyl, N-ethyl-3-aminopropyl, N-ethyl-4-aminobutyl, N-ethyl-5-aminopentyl, N-ethyl-6-aminohexyl, N-ethyl-7-aminoheptyl or N-ethyl-8-aminoethyl~~ and R₁ is a moiety selected from the group consisting of a hydrogen or a straight or branched C1-20 saturated or unsaturated aliphatic; aliphatic amine except for propylamine when R=H, n=1 and the aminomethyl functionality is para substituted; an alicyclic; single or multi ring aromatic; single or multi ring aryl substituted aliphatic; aliphatic substituted single or multi ring aromatic; a single or multi ring heterocyclic; a single or multi ring heterocyclic substituted aliphatic; an aliphatic substituted aromatic; and halogenated forms thereof;

R₂ can be independently selected from hydrogen, -CH₃ or -CH₂CH₃ and R₃ and R₄ may be the same or different and are independently selected from hydrogen, or fluorine;

and halogenated forms thereof, and wherein said polyamine is a non-symmetrical derivative of xylene.

3. (Canceled)


4. (Canceled)

5. (Canceled)

Application No.: 10/810,649
Amendment dated October 27, 2005
Response to Office Action dated May 3, 2005

Docket No.: 22116-00002-US2

6. (Currently Amended) The polyamine of any one of claims 1-5 or 2 wherein said structure is that of one of the following compounds A-Q, T as shown in Figure 1 :







Application No.: 10/810,649

Docket No.: 22116-00002-US2





Amendment dated October 27, 2005

Response to Office Action dated May 3, 2005



Application No.: 10/810,649
Amendment dated October 27, 2005
Response to Office Action dated May 3, 2005

Docket No.: 22116-00002-US2



7. (Currently Amended) A pharmaceutical composition useful for treating a disease or condition in which the inhibition of cell growth or proliferation is desirable, comprising a polyamine according to any one of claims 1-6 1, 2 or 6 and a pharmaceutically acceptable excipient, diluent or vehicle.

Application No.: 10/810,649
Amendment dated October 27, 2005
Response to Office Action dated May 3, 2005

Docket No.: 22116-00002-US2

8. (Original) The composition of claim 7 wherein said excipient, diluent or vehicle is pharmaceutically or cosmetically acceptable.

9. (Original) The composition of claim 7 wherein said excipient, diluent or vehicle is for topical or intra-aural administration.

10. Original) The composition of claim 7 formulated for intravenous, subcutaneous, intramuscular, intracranial, intraperitoneal, topical, transdermal, intravaginal, intranasal, intrabronchial, intracranial, intraocular, intraaural, rectal, or parenteral administration.

11. (Canceled)

12. (Canceled)

13. (Canceled)

14. (Canceled)

15. (Canceled)

16. (Canceled)

17. (Canceled)

18. (Canceled)

19. (Canceled)

20. (Canceled)

21. (Canceled)

Application No.: 10/810,649
Amendment dated October 27, 2005
Response to Office Action dated May 3, 2005

Docket No.: 22116-00002-US2

22. (Canceled)

23. (Canceled)

24. (Canceled)


25. (Canceled)

26. (Canceled)


27. (Canceled)

28. (Canceled)

29. (Currently Amended) The polyamine of claim 1 wherein said structure is that of compound Q as shown in Figure 1



30. (Currently Amended) The polyamine of claim 1 wherein said structure is that of compound B as shown in Figure 1




Application No.: 10/810,649
 Amendment dated October 27, 2005
 Response to Office Action dated May 3, 2005

Docket No.: 22116-00002-US2

31. (Canceled)

32. (Currently Amended) The polyamine of claim 1 wherein said ~~structure T~~
~~as shown in Figure 1 is~~



33. (Currently Amended) The polyamine of claim 1 wherein said structure ~~U~~
~~as shown in Figure 1 is~~

